Professor Dani Prieto-Alhambra

Biography

Professor Dani Prieto-Alhambra is the first Oxford Professor of Regulatory Health Data Sciences.

He is a clinician scientist with over 10 years of clinical experience in the NHS, and an expert in the analysis and interpretation of routinely collected health data to inform drug, vaccine, and device use, safety, and effectiveness.

Dani came to Oxford as a visiting scientist in 2009, and came back as a postdoctoral researcher in 2012. Since then, he has been involved and championed multiple national and international initiatives to generate and implement best practices in the generation and use of real world evidence, with a focus on regulatory sciences and decision making. He leads a multidisciplinary team of over 40 people at the Botnar Research Centre, NDORMS.

Among his top most recent publications are:

1. Li X, Guo Y, …, Prieto-Alhambra D, Burn E. Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study. Lancet Reg Health Eur. 2026 Jan 21;61:101556. doi: 10.1016/j.lanepe.2025.101556.
2.  López-Sánchez I, …, Prieto-Alhambra D, Duarte-Salles T, Newby D. Comorbidities, medication use, and overall survival in eight cancers: a multinational cohort study of 1.7 million patients across Europe. Lancet Reg Health Eur. 2026 Jan 22;63:101585. doi: 10.1016/j.lanepe.2025.101585.
3. Gratton J, Arlett P, Ehmann F, Prieto-Alhambra D, Verpillat P, Cormier E, Norstedt I, Torqui A, Lamas Díaz MJ, Laplaza Santos C, Pirmohamed M. Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action. Nat Rev Drug Discov. 2026 Feb;25(2):79-80. doi: 10.1038/d41573-025-00178-9.
4. Bellas L, …, Prieto-Alhambra D, Jödicke AM, Prats-Uribe A. Secular Trends in the Use of Valproate-Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study. Pharmacoepidemiol Drug Saf. 2025 Oct;34(10):e70232. doi: 10.1002/pds.70232.
5. Pineda-Moncusí M, …, Prieto-Alhambra D, Rijnbeek PR, Burkard T; Drug Shortages EHDEN Study Group. Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study. Lancet Public Health. 2025 Oct;10(10):e835-e847. doi: 10.1016/S2468-2667(25)00194-X.
6. Haber R, Webster-Clark M, Pratt N, Barclay N, Li X, Maro JC, Platt RW, Prieto-Alhambra D, Filion KB. Core Concepts in  Pharmacoepidemiology: Multi-Database Distributed Data Networks. Pharmacoepidemiol Drug Saf. 2025 Jul;34(7):e70177. doi: 10.1002/pds.70177.
7.  Raventos B, Prieto-Alhambra D. Real-world evidence for regulatory purposes: The example of DARWIN EU®. Farm Hosp. 2025 Mar-Apr;49(2):62-64. English, Spanish. doi: 10.1016/j.farma.2025.02.011. Epub 2025 Mar 18. PMID: 40102084.
8. Guo Y, Raventós B, …, Prieto-Alhambra D, Burn E, Jödicke AM. Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones. Pharmacoepidemiol Drug Saf. 2024 Oct;33(10):e70022. doi: 10.1002/pds.70022.
9. Alcalde-Herraiz M, Català M, Prats-Uribe A, Paredes R, Xie J, Prieto-Alhambra D. Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank. Nat Commun. 2024 Oct 9;15(1):8739. doi: 10.1038/s41467-024-52890-6.
10. Tadrous M, Aves T, Fahim C, Riad J, Mittmann N, Prieto-Alhambra D, et al. Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making. J Clin Epidemiol. 2024 Dec;176:111545. doi: 10.1016/j.jclinepi.2024.111545.

Positions

• Professorial Fellow in Regulatory Health Data Sciences
• Professor of Regulatory Health Data Sciences, NDORMS
• Fellow of the International Society of Pharmaco-Epidemiology (ISPE)

Subjects

• Clinical Medicine

Associations

• Governing Body
• Professorial Fellow